Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India
Navidea Biopharmaceuticals (NYSE American: NAVB) announced regulatory approval for Lymphoaim (Tc99m tilmanocept) by India's Central Drugs Standard Control Organisation. This agent is designed for imaging and intraoperative detection of sentinel lymph nodes in adult patients with breast cancer, melanoma, or localized squamous cell carcinoma. Sayre Therapeutics will manage commercialization in India under an exclusive distribution agreement, anticipated to generate new revenue for Navidea and advance its pipeline products.
- Regulatory approval for Lymphoaim in India enhances market presence.
- Exclusive distribution agreement with Sayre Therapeutics expected to generate new revenue.
- Dependence on successful commercialization and market acceptance of Lymphoaim.
- Existing operational losses and uncertainty surrounding future profitability.
Tc99m tilmanocept is approved for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adult patients with breast cancer, melanoma, or localized squamous cell carcinoma of the oral cavity. External imaging and intraoperative evaluation may be performed using a gamma detection device. Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.
Sayre Therapeutics will lead Lymphoaim commercialization efforts in
Dr.
Mr. Shukrit Sudhir Chimote, Chief Executive Officer for Sayre, said, “Lymphoaim, a radioactive diagnostic agent, would benefit surgeons in guiding sentinel lymph node biopsies. This product fits well with Sayre’s mission of providing novel treatment solutions, and will certainly help boost our presence in the surgical oncology segment.”
About Sayre Therapeutics
About Navidea
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other
Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005445/en/
Investor Relations Contact
Vice President of Operations
614-822-2365
jsmith@navidea.com
Source:
FAQ
What regulatory approval did Navidea receive for Lymphoaim?
What is the purpose of Lymphoaim (Tc99m tilmanocept)?
How will Lymphoaim be commercialized in India?
What impact does Lymphoaim's approval have on Navidea's revenue?